RPG Life Sciences Limited — Earnings Release 2025

Nov 7, 2024

==> picture [65 x 53] intentionally omitted <==

==> picture [160 x 62] intentionally omitted <==

Q2 FY25: Revenue Up by 12% Y-o-Y and 4% Q-o-Q. PBT before exceptional items Surges 22% Y-o-Y and 18% Q-o-Q. EBITDA Margin Hits 27.8%.

Mumbai, 7 November, 2024 : RPG Life Sciences Limited has announced its unaudited financial results for the second quarter and half year ended September 30, 2024.

Q2 FY25 Highlights	Y-o-Y Revenue from operations	Y-o-Y PBT before exceptional items
	Rs 172.21 crores – up from Rs 153.58 crores	Rs 42.39 crores – up from Rs 34.79 crores
H1 FY25 Highlights	Rs 337.63 crores – up from Rs 301.36 crores	Rs 78.39 crores – up from Rs 64.56 crores

RPG Life Sciences, a part of RPG Enterprises, engaged in the manufacturing and marketing of pharmaceutical products, posted a jump in PBT before exceptional items of 22% Y-o-Y and 18% Q-o-Q for Q2 FY25, maintaining the upward trajectory in EBITDA margins, which improved from 25.5% to 27.8% Y-o-Y. Revenue from operations registered a growth of 12% Y-o-Y and a growth of 4% Q-o-Q at Rs 172.21 crores for Q2 FY25. For H1 FY25 too, the company posted a jump in PBT before exceptional items of 21% Y-o-Y and recorded EBITDA margin expansion from 24.3% to 26.5% Y-o-Y. Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25.

Mr. Yugal Sikri, Managing Director, RPG Life Sciences Ltd. said, “In Q2 FY25, the overall performance of the Company continued to be strong. Revenue and PBT before exceptional items grew by 12% and 22% respectively Y-o-Y. EBITDA margin retained its 5-year long upward trajectory growing from 25.5% to record 27.8% Y-o-Y. The Company continues to remain debt-free.

Thanks to our well-crafted transformation agenda, diligently pursued over the past five years, our first growth engine, Domestic Formulations business, has continued to register profitable and healthy growth consistently higher than the market basis the five key initiatives - building some of our iconic “Textbook” brands like Naprosyn into megabrands through a comprehensive life cycle management program, shaping the successful products like Azoran into a multiproduct portfolio (Immunosuppressants) by leveraging our existing strong customer/brand franchise, building the futuristic portfolio of MABs into a formidable product segment through multi-branding strategy, replicating our smart and successful Rheumatology portfolio entry strategy to enter more specialties like Gastro and Derma, and deploying digital and productivity enhancement measures to ensure consistent salesforce productivity gains.

We are now shaping our International Formulations and API businesses to emerge as second and third growth engines. For this to happen, while we are on course to modernize both our API and Formulations plants - by infusion of significant capex, our modernized R&D laboratories are also working to build a smart product pipeline. The International Formulations business is now registering healthy double-digit growth, and the API business is also showing promising growth.

Our structural approach of cost optimization has helped us explore newer avenues in our operations to achieve cost efficiencies, thereby helping us to maintain our uninterrupted Y-o-Y margin expansion trajectory.

Cash that would be generated by assignment of surplus vacant leasehold land at our Navi Mumbai plant will add to our existing cash surplus which we are actively working to deploy gainfully for business expansion.”

RPG Life Sciences Ltd (www.rpglifesciences.com):

RPG Life Sciences Ltd, part of RPG Enterprises, is an integrated pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. The company is a researchbased pharmaceutical company, producing a wide range of quality, affordable medicines. Its brands are highly trusted by healthcare professionals and patients.

RPG Enterprises (www.rpggroup.com):

RPG Enterprises, established in 1979, is one of India’s fastest growing business groups with a turnover of US$ 4.8 Billion. The group has diverse business interests in the areas of Infrastructure, Tyres, Pharma, IT and Specialty as well as in emerging innovation-led technology businesses.

==> picture [134 x 28] intentionally omitted <==

Media Contact: Priya Singh – 81690 22988 | priya@rpg.in